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Abstract – Penaresidin A and B are sphingosine-related natural products that 
contain a 2,3,4-trisubstituted azetidine ring and a long alkyl side chain. 
Stereoselective construction of the trisubstituted azetidine ring is a crucial step in 
the synthesis of penaresidins, and all the currently reported syntheses have been 
accomplished by SN2-type cyclization of a precursor having a 1-amino-2,3-diol 
structure with three continuous stereocenters. This cyclization is strongly 
influenced by the configurations of the vicinal amino alcohol moieties of the 
precursors. This review focuses on the SN2-type cyclizations that are used to 
construct the trisubstituted azetidine ring in penaresidin synthesis. 
Dedicated to Professor Kaoru Fuji on the occasion of his 80th birthday. 
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1. INTRODUCTION 
Penaresidin A (1) and B (2) were first isolated as a mixture from the Okinawan marine sponge Penares sp. 
by the Kobayashi group in 1991 (Figure 1).1 These compounds are regarded as sphingosine-related natural 
products and comprise a 2,3-anti-3,4-syn-trisubstituted azetidine ring core and a long alkyl side chain. The 
 
absolute configurations of 1 and 2 were determined to be (2S,3R,4S,15S,16S) and (2S,3R,4S,15S), 
respectively, by synthetic studies2,3 and NMR analysis4 using the modified Mosher method. Penaresidins 1 
and 2 exhibit potent actomyosin ATPase-activating activities,1 and 2 shows modest cytotoxicity against 
murine lymphoma L1210 cells.5 Several stereoisomers 3–7 and analogs 8–19 of 1 and 2 (Figure 2) have 
also been reported, and some of them have been evaluated using biological assays. The side chain analogs 
(16S)- and (16R)-penazetidine 8 and 9 have been demonstrated to exhibit protein kinase C inhibitory 
activities.6 The straight side chain analogs 10–15 also provided interesting results,5 with the 2,3-anti-3,4-
syn- and 2,3-anti-3,4-anti-isomers 10 and 11 exhibiting higher cytotoxicity against human lung (A549) and 
colon (HT29) cancer cells than 2. Analogs 10, 13 (ent-10), and 14 (ent-11) exhibit antibacterial activity 
against Gram-positive bacteria (Bacillus subtilis, Micrococcus luteus, and Staphylococcus aureus), and 11 
exhibits antibacterial activity against both Gram-positive bacteria and the Gram-negative bacterium 
Escherichia coli.5 Moreover, the N-acyl-O-glycosylated straight side chain analog of 10, i.e., α-18 (RCAI-
18), has been reported to exhibit potent cytokine-inducing activity in mouse killer T cells.7 Accordingly, 
the unique structural features and interesting biological activities of penaresidins, as well as their 
stereoisomers and analogs, have attracted considerable attention as synthetic targets. 
 
 
Figure 1. Structures of penaresidin A (1) and B (2) 
 
 
 
Figure 2. Structures of the currently reported penaresidin stereoisomers and analogs 3–19 
 
In the synthesis of these targets, a key issue is the construction of the trisubstituted azetidine structure 
because an azetidine is a highly strained four-membered heterocycle, which is rather difficult to form.8 
Among the various methods for azetidine synthesis developed to date, SN2-type cyclization is the most 
common. Indeed, all of the reported syntheses of penaresidins, their stereoisomers, and their analogs have 
been accomplished using this methodology. These SN2-type cyclizations are classified into two categories 
(Scheme 1): i) those proceeding from 2-amino precursors 20, and ii) those proceeding from 4-amino 
precursors 21. Both precursors should have three continuous stereocenters at the C-2, C-3, and C-4 positions. 
For the synthesis of natural penaresidins having 2,3-anti-3,4-syn-azetidine structures, stereoselective 
preparation of either 2,3-anti-3,4-anti-20 or 2,3-syn-3,4-syn-21 species is required. Precursors 20 are used 
more than 21 because penaresidins are biogenetically related to natural phytosphingosines. The cyclization 
 
of 20 and 21 is dependent on their structural features, such as their configurations, protecting groups, and 
side chains. Thus, it is very important to understand the effects of such structural features on the cyclization. 
Herein, we present a review of the synthesis of penaresidins, their stereoisomers, and their analogs, mainly 
focusing on the construction of azetidine rings by SN2-type cyclizations. We also consider the 
stereoselective preparation of precursors for the cyclization. 
 
 
Scheme 1. SN2-type cyclizations in the synthesis of penaresidins, their stereoisomers, and their analogs 
 
2. CONSTRUCTION OF AZETIDINE RINGS FROM 2-AMINO PRECURSORS 
2.1 CONSTRUCTION AFTER INTRODUCTION OF THE SIDE CHAIN 
2-Amino precursors are often employed for the SN2-type cyclization. In most cases, these precursors bear 
a side chain moiety. The Mori group succeeded in the cyclization of several 2,3-anti-3,4-anti-precursors 
for the first syntheses of penaresidin A (1), B (2), as well as their stereoisomers 3–5 and analogs 8, 9 in the 
mid-1990s.2,3,9 The synthesis of the 2,3-anti-3,4-anti-precursor 29 proceeded from (S)-Garner’s aldehyde 
[(S)-23] (Scheme 2). Based on Garner’s procedure for the synthesis of sphingosines,10 the reaction of (S)-
23 with the acetylide of alkyne 24 afforded the anti-adduct 25 diastereoselectively. Adduct 25 was then 
converted into N-Ts-O-tert-butyldimethylsilyl (TBS)-protected sphingosine derivative 26 in three steps. 
Epoxidation of 26 with m-chloroperbenzoic acid (mCPBA) gave the desired 3,4-anti-epoxide 27 in only 
42% yield accompanied by the undesired 3,4-syn-epoxide 28 in 56% yield. After separation by column 
chromatography, reductive ring-opening of 27 with diisobutylaluminium hydride (DIBAL-H) proceeded 
regioselectively to afford the 2,3-anti-3,4-anti-precursor 29. The other precursors 30–35 shown in Table 1 
were synthesized in similar manner to 29. Construction of azetidine rings from 2,3-anti-3,4-anti-precursors 
29–35 was performed in two steps (Table 1). Thus, mesylation of 29–35 followed by SN2-type cyclization 
with NaH in THF at room temperature for 23 or 24 h successfully produced 2,3-anti-3,4-syn-azetidines 36–
42 in high yields (72–88%) from 29 to 35, respectively. Penaresidins 1–5, 8, and 9 were synthesized from 
36 to 42 by removal of the protecting groups in two steps. 
 
 
 
Scheme 2. Synthesis of 2-amino precursor 29.2,3 Boc = tert-butoxycarbonyl 
 
Table 1. Mesylation and subsequent SN2-type cyclization of 29–35 and synthesis of penaresidins 1–5, 8, 
and 92,3,9 
 
 
 
Mori and colleagues applied their method to the construction of 2,3-anti-3,4-syn-azetidine 45 and 2,3-anti-
3,4-anti-azetidine 48 having straight alkyl side chains for the synthesis of N-acyl-O-glycosylated analogs 
18 (RCAI-18 and 19) and 19 (RCAI-49 and 50) (Scheme 3).7 To synthesize azetidine 45 with the same 
stereochemistries of the azetidine ring as 36–42, the 2,3-anti-3,4-anti-precursor 44 was obtained from (S)-
23 and 1-pentadecyne (43) in a similar manner to that by which precursor 29 was obtained. SN2-type 
cyclization of the mesylate of 44 was performed under similar reaction conditions to those used for 29–35 
to afford 2,3-anti-3,4-syn-azetidine 45 in 80% yield from 44 after 40 h. Compound 45 was converted into 
α-18 and β-18 in six steps. The 2,3-anti-3,4-syn-precursor 47 for the synthesis of 48 was prepared from 44 
through stereoinversion at the C-4 position. Thus, the oxidation of 44 under Albright-Goldman oxidation 
conditions11 gave ketone 46, which was reduced with LiEt3BH to afford 47 with high diastereoselectivity 
(dr 8:1). Cyclization of the mesylate of 47 under the same conditions as those used for 44 successfully 
generated the desired 2,3-anti-3,4-anti-azetidine 48 in 86% yield after 44 h. Azetidine 48 led to α- and β-
19 in the same manner. 
 
 
Scheme 3. Synthesis of α-18 (RCAI-18), β-18 (RCAI-19), α-19 (RCAI-49), and β-19 (RCAI-50) using 
SN2-type cyclization of the mesylates of 2,3-anti-3,4-anti- and 2,3-anti-3,4-syn-precursors 44 and 477 
 
Kobayashi and colleagues reported the SN2-type cyclization of 2,3-syn-3,4-anti-precursor 51 (Scheme 4) 
in addition to those of 2,3-anti-3,4-anti- and 2,3-anti-3,4-syn-isomers in the synthesis of the straight side 
chain analogs 10–12 and their enantiomers 13–15.5 Analogs 10, 11, 13, and 14 were synthesized from (S)- 
or (R)-23 and 43 using SN2-type cyclization of the 2,3-anti-3,4-anti- and 2,3-anti-3,4-syn-isomers according 
 
to Mori’s procedure.2,3,7,9 To synthesize 15, the 2,3-syn relation of precursor 51 was established using 
zirconium chemistry. Thus, addition of 1-alkenyl nucleophiles derived by hydrozirconation of 43 with 
Cp2Zr(H)Cl and Et2Zn to (R)-23 and subsequent treatment with aqueous AcOH gave syn-adduct 4912 in 
diastereomerically pure form after recrystallization. Precursor 51 was obtained from 49 via alkene 50 by 
Mori’s epoxidation-reduction sequence. When cyclization of 51 was performed under Mitsunobu reaction 
conditions using diisopropyl azodicarboxylate (DIAD) and Ph3P in THF at 0 °C for 12 h, the desired 2,3-
syn-3,4-syn-azetidine 52 was obtained, albeit in only 20% yield. Deprotection of 52 produced 15. Synthesis 
of 12 was accomplished from (S)-23 and 43 in the same manner as 15. 
 
 
Scheme 4. Synthesis of straight side chain analog 15 using SN2-type cyclization of 2,3-syn-3,4-anti-
precursor 515 
 
Knapp and coworkers employed a Boc group as an amino-protecting group in the 2,3-anti-3,4-anti-
precursors 60a–c for the synthesis of 1, its stereoisomer 6 and analog 17.13 Precursors 60a–c were prepared 
from the same starting material (S)-23 as that used by Mori et al. by addition of 2-(trimethylsilyl)thiazole 
(53) as a formyl anion equivalent to (S)-23 and Keck allylation of aldehyde 55 (Scheme 5). According to 
Dondonis’ procedure,14 the reaction of (S)-23 with 53 followed by treatment with tetrabutylammonium 
fluoride (TBAF) selectively produced the anti-adduct 54 (dr 92:8), which was recrystallized to provide 54 
in diastereomerically pure form. After conversion15 of 54 into aldehyde 55, Keck allylation16 using 
allyltributyltin and BF3ꞏOEt2 generated 3,4-anti-homoallylic alcohol 56 with high diastereoselectivity (dr 
10:1). Diastereomerically pure 56 was obtained by chromatographic separation. The pure diastereomer 56 
was transformed into aldehyde 57 in two steps. Extension of the side chain of 57 by Wittig reaction using 
phosphonium bromide 58a and lithium hexamethyldisilazide (LHMDS) followed by desilylation with 
TBAF gave alkene 59a, which led to the 2,3-anti-3,4-anti-precursor 60a in five steps. Synthesis of 60b and 
60c was also achieved in the same manner as 60a using 58b and 58c as phosphonium bromides, respectively. 
As shown in Table 2, SN2-type cyclization of 60a–c was performed with sodium hexamethyldisilazide 
(NaHMDS) in DMF at 0 °C to give the corresponding azetidines, the silyl groups of which were removed 
 
with TBAF to afford 61a–c in high (81–84%) yields. The desired products 17, 1, and 6 were obtained by 
acidic deprotection of 61a–c. 
 
 
Scheme 5. Preparation of 2,3-anti-3,4-anti-precursors 60a–c.13 TES = triethylsilyl 
 
Table 2. SN2-type cyclization of 60a–c and synthesis of penaresidins 17, 1, and 613 
 
 
The N-Boc-2,3-anti-3,4-anti-precursor 68 was prepared from D-glutamic acid (62) through the formation 
of the bicyclic lactam 6517 for the synthesis of penaresidin B (2) by Yoda and coworkers (Scheme 6).18 
After preparation of hydroxylactam 63 from 62 according to literature methods,19 63 was converted into 
unsaturated lactam 64 in four steps. Stereoselective dihydroxylation of 64 with a catalytic amount of OsO4 
 
in the presence of N-methylmorpholine N-oxide (NMO) followed by protection of the resulting diol group 
with 2,2-dimethoxypropane (2,2-DMP) under acidic conditions provided bicyclic lactam 65 as a single 
isomer. After treatment of alkyne 66 with BuLi, reaction of the resulting acetylide with 65 and subsequent 
reduction with NaBH4 generated secondary alcohol 67 as a mixture of diastereomers. The 2,3-anti-3,4-anti-
precursor 68 was obtained in six steps from 67. SN2-type cyclization of the mesylate of 68 with NaH in 
THF resulted in a moderate (58%) yield of 2,3-anti-3,4-syn-azetidine 69 in two steps. The amino- and 
hydroxy-protecting groups of 69 were then removed to afford 2. 
 
  
Scheme 6. Synthesis of penaresidin B (2) using SN2-type cyclization of the 2,3-anti-3,4-anti-precursor 6818 
 
Kamikawa et al. used benzyl groups as hydroxy-protecting groups in the 2,3-anti-3,4-anti-precursors 76–
78 having N-Ms, N-Boc, and N-Ts groups, respectively, for synthesizing the straight side chain analog 16 
(Scheme 7).20 Preparation of 76–78 was started from 3,5-di-O-benzyl-D-xylose (70) via amino alcohol 75. 
After conversion of 70 into aldehyde 71 in five steps, nucleophilic addition of C12H25MgBr to 71 in the 
presence of Li2CuCl4 produced the corresponding secondary alcohol as a mixture of diastereomers (dr 1:1). 
The mixture was then oxidized to ketone 72, which was reduced with Zn(BH4)2 and then acetylated to give 
acetate 73 with high diastereoselectivity (dr 95:5). After removal of the p-methoxybenzyl (PMB) group of 
73, stereoinversion of the C-2 position was conducted using SN2-type azidation to produce azide 74. 
Reduction of 74 with LiAlH4 gave 75, which was converted into 76–78 in one or two steps. The N-Ms-
precursor 76 was subjected to SN2-type cyclization with NaH in DMF to provide 2,3-anti-3,4-syn-azetidine 
79 in 62% yield in two steps. The N-Boc-precursor 77 was cyclized to give azetidine 80 in 72% yield in 
three steps. The cyclization of N-Ts-precursor 78 was also conducted, affording the corresponding azetidine 
 
81 in lower (49%) yield than those of 76 and 77. The synthesis of 16 was achieved by deprotection of 81 
under Birch reduction conditions. 
 
 
Scheme 7. Preparation and SN2-type cyclization of 2,3-anti-3,4-anti-precursors 76–78 for the synthesis of 
analog 16.20 DDQ = 2,3-dichloro-5,6-dicyano-p-benzoquinone, DMAP = 4-(dimethylamino)pyridine 
 
The N-unprotected 2,3-anti-3,4-anti-azidoalcohol 87 was employed as a precursor for the synthesis of 
penaresidin A derivative 88 by Ducrot et al. (Scheme 8).21 Azidoalcohol 87 was prepared from 1,2:5,6-di-
O-isopropylidene-α-D-glucofuranose (82). The starting material 82 was converted into 4-tosyloxy-2,5-diol 
83 in nine steps. The reaction of 83 with K2CO3 in MeOH proceeded with inversion of the C-4 configuration 
to afford epoxide 84.22 Addition of the lithium acetylide of 85 to 84 in the presence of BF3ꞏOEt2 followed 
by reduction of the alkyne moiety with Raney Ni under hydrogen afforded diol 86. Tosylation of 86 
proceeded regioselectively to afford the corresponding C-2 tosylate, which was subjected to SN2-type 
azidation to form azidoalcohol 87 with inversion of the C-2 configuration. Reaction of 87 with Ph3P in 
benzene proceeded through the formation of an iminophosphorane intermediate23 to afford the desired 
penaresidin derivative 88 in 36% yield, even though a substantial amount (28% yield) of amino alcohol 89 
was formed by hydrolysis of the iminophosphorane. 
 
 
 
Scheme 8. Preparation and cyclization of 2,3-anti-3,4-anti-azidoalcohol 87 for synthesis of the penaresidin 
A derivative 8821 
 
2.2 CONSTRUCTION BEFORE INTRODUCTION OF THE SIDE CHAIN 
In most cases in which 2-amino precursors are employed, the azetidine rings are constructed at a later stage 
after the introduction of the side chains. This may be because this late-stage construction can minimize the 
exposure of the reactive azetidine structure to the subsequent reactions required to obtain the target 
compounds. However, synthetic approaches in which the azetidine ring is constructed before introduction 
of the side chain moiety have been explored. Such approaches make it much easier to synthesize penaresidin 
analogs having different alkyl side chains. In these kinds of approaches, the azetidine fragments and the 
side chains are coupled at the later stage by olefination reactions, such as Wittig or Julia-Kocienski reactions. 
Lin and colleagues succeeded in the synthesis of 1 and 4 by construction of the azetidine ring before 
introduction of the side chain moiety by the Wittig reaction (Scheme 9).24 In addition, they first performed 
the enantioselective synthesis of a 2,3-anti-3,4-anti-precursor. The N-Ts-O-Bn-precursor 96 was 
synthesized from 1,4-pentadien-3-ol (90). According to Jäger’s procedure,25 epoxide 91 was obtained 
exclusively from 90 by Sharpless asymmetric epoxidation. The primary hydroxy group of 91 was 
benzylated to give 92. Sharpless asymmetric dihydroxylation26 of 92 using 93 as a chiral ligand and 
subsequent protection of the resulting 1,2-diol moiety afforded 94 with high diastereoselectivity (dr 11:1). 
Ring-opening27 of 94 with NaN3 regioselectively provided azide 95, which was transformed into precursor 
96 in five steps. The cyclization of 96 under Mitsunobu reaction conditions using diethyl azodicarboxylate 
(DEAD) and Ph3P in CH2Cl2 proceeded smoothly to form 2,3-anti-3,4-syn-azetidine 97 in 60% yield. 
Deprotection of 97 and subsequent oxidation yielded aldehyde 98. The Wittig reaction of 98 with 
phosphonium bromide 99 and sodium methylsulfinylmethylide in THF successfully afforded a mixture of 
 
(Z)- and (E)-isomers of the desired coupling product 100 in 60% yield, demonstrating that the azetidine 
structure can be stable under Wittig reaction conditions. Compound 100 was converted into 1 in four steps. 
Synthesis of 4 was also achieved in similar manner using 101 instead of 99. 
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Scheme 9. Synthesis of penaresidin A (1) and its stereoisomer 4 using SN2-type cyclization of the 2,3-anti-
3,4-anti-precursor 96 and the late-stage introduction of a side chain by the Wittig reaction.24 DIPT = 
diisopropyl tartrate, MS4A = molecular sieves 4 Å, TBAI = tetrabutylammonium iodide, TBHP = tert-
butyl hydroperoxide 
 
The Julia-Kocienski reaction was employed for the late-stage introduction of the side chain in the synthesis 
of penaresidin A (1) by Raghavan and Krishnaiah (Scheme 10).28 They also used a benzyl group as an 
amino-protecting group in the 2,3-anti-3,4-anti-precursor 110, which was enantioselectively synthesized 
from acrolein (102). The starting material 102 was transformed into the unsaturated sulfinylimine 103 in 
two steps. Stereoselective addition of the anion of chiral sulfoxide 104 to 103 in THF afforded the desired 
sulfinamide 105 with high diastereoselectivity (dr 96:4). Compound 105 was converted into N-Bn-N-2-
nitrobenzenesulfonyl (Ns)-protected allylic amine 106 in three steps. When 106 was treated with NBS and 
H2O, bromohydrin 107 was formed as a single isomer. Epoxy alcohol 108 was obtained from 107 in four 
 
steps. Ring-opening of 108 with aq. H2SO4 regioselectively afforded 2,3-anti-3,4-anti-1,3,4-triol 109, 
which was converted into 2,3-anti-3,4-anti-precursor 110 in three steps. Reaction of 110 with 2-
mercaptoethanol and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in acetone at room temperature proceeded 
through removal of the Ns group and subsequent SN2-type cyclization of the N-Bn intermediate 111 to give 
2,3-anti-3,4-syn-azetidine 112 in 91% yield after 8 h. Aldehyde 113 was synthesized from 112 in two steps. 
The Julia-Kocienski reaction of 113 and 1-phenyl-1H-tetrazol-5-yl (PT)-sulfone 114 was performed with 
potassium hexamethyldisilazide (KHMDS) in THF, and the coupling product alkene 115 was obtained as 
a mixture of (E)- and (Z)-isomers in 93% yield. This result demonstrates the stability of azetidine rings 
under Julia-Kocienski reaction conditions. Hydrogenation and deprotection of 115 led to the formation of 
1. 
Subba Reddy and coworkers also employed the Julia-Kocienski reaction for the late-stage introduction of 
the side chain in the synthesis of 1 (Scheme 11).29 Preparation of N-Ts-O-Bn-2,3-anti-3,4-anti-precursor 
120 for SN2-type cyclization proceeded from 3,4,6-tri-O-benzyl-D-galactal (116). Allylic alcohol 117 was 
synthesized from 116 in two steps and then subjected to Sharpless asymmetric epoxidation30 and subsequent 
ring-opening with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al) to give triol 118 selectively. 
After protection of the 1,3-diol moiety of 118 as its acetal, the remaining hydroxy group was replaced with 
an azide group with inversion of the stereochemistry in two steps to yield azide 119. Conversion of 119 
into 2,3-anti-3,4-anti-precursor 120 was accomplished in four steps. The 2,3-anti-3,4-syn-azetidine 121 
was obtained in moderate (51%) yield from 120 through cyclization of the mesylate of 120 with NaH in 
THF at 0 °C. After conversion of 121 into aldehyde 122 in two steps, coupling of 122 with PT-sulfone 123 
with KHMDS successfully afforded alkene 124 in 70% yield. Reduction and deprotection of 124 produced 
1. 
In the construction of azetidine rings from 2-amino precursors, the SN2-type cyclization of 2,3-anti-3,4-
anti-precursors produces 2,3-anti-3,4-syn-azetidines in moderate to excellent yields, allowing the synthesis 
of natural penaresidins. The 2,3-anti-3,4-syn-precursors are cyclized to 2,3-anti-3,4-anti-azetidines in high 
yields. In contrast, the cyclization of 2,3-syn-3,4-anti-precursors results in very low yields of the 2,3-syn-
3,4-syn-azetidines. Recent studies have employed synthetic strategies in which the side chain was 
introduced after formation of the azetidine ring. Such strategies can be utilized to synthesize various side 
chain analogs. 
 
 
  
Scheme 10. Synthesis of penaresidin A (1) using SN2-type cyclization of 2,3-anti-3,4-anti-precursor 110 
and the late-stage introduction of a side chain by the Julia-Kocienski reaction.28 LDA = lithium 
diisopropylamide, TBDPS = tert-butyldiphenylsilyl 
 
 
 
Scheme 11. Synthesis of penaresidin A (1) using SN2-type cyclization of 2,3-anti-3,4-anti-precursor 120 
and the late-stage introduction of a side chain by the Julia-Kocienski reaction29 
 
3. CONSTRUCTION OF AZETIDINE RINGS FROM 4-AMINO PRECURSORS 
Several researchers including our group have synthesized penaresidins, their stereoisomers, and their 
analogs using construction of the azetidine ring from 4-amino precursors. Lin et al. reported that the SN2-
type cyclization is strongly influenced by the substitution pattern of the precursors in the synthesis of 
penaresidins 1, 6, and 7 (Scheme 12).24,31 To synthesize 6 and 7, N-Ts-1-O-TBS-3-O-Bn-2,3-anti-3,4-syn-
4-amino precursor 131 was prepared from 1,4-pentadien-3-ol (90). According to the literature,32 90 was 
selectively converted into epoxide 125 by Sharpless asymmetric epoxidation. Reaction of 125 with 
Grignard reagent 126 and CuI afforded 127, whose hydroxy group was displaced by an azide group with 
inversion of configuration to form 128. After reduction of the azide group of 128 followed by protection, 
Sharpless asymmetric dihydroxylation of the resulting 129 using 130 exclusively produced the 
corresponding 1,2-diol, whose primary hydroxy group was selectively protected to generate precursor 131. 
When cyclization of 131 was performed under Mitsunobu reaction conditions using DEAD and Ph3P in 
THF at 0 °C, the desired 2,3-syn-3,4-syn-azetidine 132 was afforded in excellent (92%) yield, which is in 
stark contrast to the similar cyclization of 2,3-syn-3,4-anti-2-amino precursor 51 that gave 2,3-syn-3,4-syn-
azetidine 52 in only 20% yield (Scheme 4).5 Removal of the 2-tetrahydropyranyl (THP) group of 132 
followed by oxidation afforded aldehyde 133, which was converted into 6 and 7 in four steps. The SN2-
type cyclization of 2,3-syn-3,4-syn-4-amino precursor 134, a 2-epimer of 131, was explored for the 
synthesis of natural penaresidin 1.24 However, the desired 2,3-anti-3,4-syn-azetidine 135 was not obtained. 
 
 
  
Scheme 12. Synthesis of penaresidins 6 and 7 using SN2-type cyclization of 2,3-anti-3,4-syn-precursor 131 
and the unsuccessful cyclization of 2,3-syn-3,4-syn-precursor 13424,31 
 
Yoda and colleagues succeeded in the cyclization of 2,3-syn-3,4-syn-4-amino precursor 140 having Boc 
and MOM groups as N- and O-protecting groups, respectively, in the synthesis of 2 from 2,3,5-tri-O-benzyl-
D-arabinofuranose (136) (Scheme 13).33 After conversion of 136 into furanosylamine 137 according to the 
literature,34 stereoselective addition of the acetylide of 138 to 137 and subsequent oxidative degradation 
with pyridinium chlorochromate (PCC) produced lactam 139 with > 99% de. Compound 139 was 
transformed into precursor 140 in eight steps. The SN2-type cyclization of the mesylate of 140 was 
performed with NaH in THF to afford the 2,3-anti-3,4-syn-azetidine 141 in moderate (50%) yield in two 
steps. Yoda suggested that the different result observed for the cyclization of 140 from that observed for 
134 (Scheme 12)24 is due to the steric bulkiness of the amino (N-Boc for 140; N-Ts for 134) and hydroxy 
(1,3-di-O-MOM for 140; 1-O-TBS and 3-O-Bn for 134) protecting groups. Natural penaresidin 2 was 
obtained from 141 by acidic treatment. 
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Scheme 13. Synthesis of penaresidin B (2) using SN2-type cyclization of 2,3-syn-3,4-syn-precursor 14033 
 
 
Scheme 14. Synthesis of N-Ts-penaresidin B 149 using SN2-type cyclization of 2,3-syn-3,4-syn-precursor 
14435 
 
Liu and colleagues reported a better result for the SN2-type cyclization of the 2,3-syn-3,4-syn-4-amino 
precursor in the synthesis of N-Ts-penaresidin B 149 (Scheme 14).35 They employed precursor 144 having 
a shorter alkyl side chain and N-Ts and O-Ac groups for the cyclization. The synthesis of 144 proceeded 
with regio- and stereoselective tandem hydroamination/glycosylation of 3,4,6-tri-O-acetyl-D-galactal (142), 
as developed by the authors.36 Thus, reaction of 142 with benzyl alcohol and tosylamide in the presence of 
 
BF3ꞏOEt2 proceeded to give amino sugar 143 exclusively. Conversion of 143 into the precursor 144 was 
accomplished in three steps. Cyclization of 144 was conducted under Mitsunobu reaction conditions using 
DIAD and Ph3P in THF at room temperature for 12 h to furnish 2,3-anti-3,4-syn-azetidine 145 in high 
(75%) yield, although 144 has a bulky Ts group as an N-protecting group. Azetidine 145 was converted 
into N-Ts-penaresidin B 149 using the Julia-Kocienski reaction of aldehyde 146 with PT-sulfone 147 to 
form 148. 
Recently, we explored the SN2-type cyclization of 2,3-syn-3,4-syn-precursors 155a–d and 2,3-syn-3,4-anti-
precursor 156 to evaluate the effects of their hydroxy-protecting groups and configurations in the synthesis 
of 2 and 10.37 Precursors 155a–d and 156 were synthesized from diethyl D-tartrate (150) using 
stereoselective reduction38 of allylic ketone 151 with different reducing agents (Scheme 15). After 
conversion of 150 into 151 in seven steps, 151 was reduced with Zn(BH4)2 to afford 3,4-anti-homoallylic 
alcohol 152 with high diastereoselectivity (dr 8:1). Conversely, reduction of 151 with L-selectride provided 
3,4-syn-homoallylic alcohol 153 as a single isomer. To synthesize 155a–d, substitution of the hydroxy 
group of 3,4-anti-alcohol 152 with an azide group with inversion of the stereochemistry furnished azide 
154, which was transformed into 155a–d in five or seven steps. Precursor 156 was synthesized from 3,4-
syn-alcohol 153 in the same manner. The SN2-type cyclization of 155a–d and 156 with NaH is shown in 
Table 3. We found that the 1-OH protecting group has a considerable effect on the cyclization of 2,3-syn-
3,4-syn-precursors and that the Bn group is the most suitable protecting group. Furthermore, the 3-OH 
group is not important for the cyclization. The best result was obtained using the 1-O-Bn-3-O-PMB-
precursor 155d at 80 °C in DMF, whereby 2,3-anti-3,4-syn-azetidine 157d was obtained in 92% after 0.75 
h (entry 5). In contrast to the 2,3-syn-3,4-syn-precursor 155a (entry 1), 2,3-syn-3,4-anti-precursor 156 was 
cyclized smoothly with NaH in THF at room temperature to afford 2,3-anti-3,4-anti-azetidine 158 in high 
(82%) yield after 19 h (entry 6). The late-stage introduction of the alkyl side chain was accomplished by 
olefin cross-metathesis (Scheme 16). Thus, after removal of the PMB group of 157d, the resulting 157e 
was treated with alkenes 159a and 159b in the presence of Grubbs 2nd catalyst to give high yields of 
coupling products 160a and 160b, which were converted into 10 and 2 in four steps. 
 
 
 
Scheme 15. Preparation of 2,3-syn-3,4-syn-precursors 155a–d and 2,3-syn-3,4-anti-precursor 15637 
 
Table 3. SN2-type cyclization of 155a–d and 15637 
 
 
 
 
Scheme 16. Synthesis of penaresidin B (2) and the straight side chain analog 1037 
 
In the construction of azetidine rings from 4-amino precursors to synthesize penaresidins, the cyclization 
of 2,3-syn-3,4-syn-precursors is rather difficult. In this cyclization, the choice of the 1-hydroxy-protecting 
group and alkyl side chain is important. In contrast, 2,3-syn-3,4-anti- and 2,3-anti-3,4-syn-precursors are 
smoothly cyclized to 2,3-anti-3,4-anti- and 2,3-syn-3,4-syn-azetidines, respectively, in high to excellent 
yields. Similarly to the synthesis of penaresidins, their stereoisomers, and their analogs using the SN2-type 
cyclization of 2-amino precursors, recent syntheses using the cyclization of 4-amino precursors have 
employed the late-stage introduction of the side chains. 
 
4. CONCLUSIONS 
Penaresidins have attracted attention as synthetic targets because they have interesting structures, including 
2,3,4-trisubstituted azetidine cores and alkyl side chains, in addition to their potent biological activities. 
Owing to the structural relation between penaresidins and phytosphingosines, most syntheses of 
penaresidins are achieved using construction of the azetidine ring by the SN2-type cyclization of 2-amino 
precursors (phytosphingosine derivatives). In addition, their regioisomeric 4-amino precursors have also 
been used. By comparison of the cyclizations reported for penaresidin synthesis, we identified interesting 
features of the cyclization, as shown in Table 4. Because the precursors possess different substituents, 
amino (N), hydroxy (O), and leaving (L) groups, on three continuous stereocenters, they can be classified 
into four categories by their relative stereochemistries, i.e., i) A (N,O-anti-O,L-anti), ii) B (N,O-syn-O,L-
syn), iii) C (N,O-syn-O,L-anti), and iv) D (N,O-anti-O,L-syn). Conversely, azetidines having two alkyl and 
one hydroxy group on the stereocenters can be classified into three categories, i.e., i) X and X’ (anti-syn), 
ii) Y (syn-syn), and iii) Z (anti-anti). Precursors A and B give azetidines X and X’. Their N,O-syn-O,L-
anti- and N,O-anti-O,L-syn-isomers C and D provide Y and Z, respectively. The cyclization is strongly 
dependent on the configurations of the N and O groups (vicinal amino alcohol moieties) in the precursors. 
Thus, the cyclization of N,O-anti-precursors A and D successfully produces azetidines X and Z, 
 
respectively. A silyl protecting group would be preferred as the hydroxy-protecting group for the 
cyclization of A (see Chapter 2). The cyclization of N,O-syn-isomers B and C is rather problematic and 
often provides very low yields of X’ and Y. The cyclization of B is strongly affected by the steric bulkiness 
of oxymethyl group (CH2OPG, R4, PG = protecting group). A benzyloxymethyl group as R4 is beneficial 
for obtaining azetidine X’ in higher yields (see Chapter 3, Table 3). Shorter alkyl groups as R2 are also 
preferred for the cyclization of B (see Chapter 3, Schemes 13 and 14, Table 3). In the case of the cyclization 
of C, both alkyl and oxymethyl groups as substituents R2 and R4, respectively, are required for a higher 
yield of azetidine Y (see Chapter 2, Scheme 4, and Chapter 3, Scheme 12). In all cases, choice of the amino-
protecting group is not important for the cyclization. We hope that this review would be useful for 
synthesizing highly substituted azetidine derivatives. 
 
Table 4. Summary of SN2-type cyclizations for the synthesis of penaresidins, their stereoisomers, and their 
analogs 
entry precursor azetidine yield ref
1
2
3
4
moderate to
excellent
very low to
excellent
low or
excellent
high
notes
R2: shorter alkyl group is preferred
and/or
R4: CH2OBn group is preferred
2, 3, 5, 7, 9,
13, 18, 20, 21,
24, 28, 29
24, 33, 35, 37
5, 31
7, 37
both R2: alkyl and R4: CH2OPG
groups are required
PG (in R2) and R3: silyl group
would be preferred
SN2-type cyclization
OR3
R1HN L
A (N,O-anti-O,L-anti)
R2 = CH2OPG, R
4 = alkyl
anti
anti
R4R2
N
OR3
R1
X (anti-syn)
anti syn
R2 R4
OR3
R1HN L
B (N,O-syn-O,L-syn)
R2 = alkyl, R4 = CH2OPG
R4R2
N
OR3
R1
X' (anti-syn)
R2R4
OR3
R1HN L
C (N,O-syn-O,L-anti)
R4R2
N
OR3
R1
Y (syn-syn)
R2 R4
OR3
R1HN L
D (N,O-anti-O,L-syn)
R4R2
N
OR3
R1
Z (anti-anti)
R2 R4
OR3
R1HN L
precursors
L = leaving group
R4R2
N
OR3
R1
azetidines
R2 R4
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